AIRNA nets $155M series B to launch clinical test of RNA editing tech
AIRNA, a transatlantic RNA editing biotech, is preparing to launch its lead asset into clinical trials with fuel from a $155 million series B fundraise.
AIRNA, a transatlantic RNA editing biotech, is preparing to launch its lead asset into clinical trials with fuel from a $155 million series B fundraise.
